COMP <GO>
CSTL vs UNH // EV/EBITDA & P/E VALUATION
Castle Biosciences Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CSTL 2
— UNH 9
■ METRIC PARITY
LAST: $38.51 (+4.99%) • MKT CAP: $1.18B
valuation
—
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CSTL VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CSTL | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.40% | 88.57% | -9.17 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -9.30% | 11.47% | -20.77 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.41% | 6.48% | -4.07 | UNH | /fcf-yield <GO> |
| Operating Margin | -12.40% | 4.82% | -17.22 | UNH | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 3.14% | -10.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 3.70% | 6.46% | -2.76 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.97 | 3.12 | +3.85 | CSTL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.9 | 59.2 | +1.67 | CSTL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.18B | $368.83B | -$367.65B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CSTL REV | UNH REV | CSTL GROSS % | UNH GROSS % | CSTL FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $344.2M | $447.57B | 79.4% | 88.7% | $28.3M | $16.07B |
| FY 2024 | $332.1M | $400.28B | 81.9% | 88.3% | $36.5M | $20.70B |
| FY 2023 | $219.8M | $371.62B | — | 89.6% | -$5.6M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CSTL // BETA —
UNH // BETA 0.33